nodes	percent_of_prediction	percent_of_DWPC	metapath
Nortriptyline—CYP2E1—liver cancer	0.366	0.645	CbGaD
Nortriptyline—ALB—liver cancer	0.201	0.355	CbGaD
Nortriptyline—HTR2C—Sorafenib—liver cancer	0.0725	0.297	CbGbCtD
Nortriptyline—CYP3A5—Sorafenib—liver cancer	0.0354	0.145	CbGbCtD
Nortriptyline—CYP2C19—Sorafenib—liver cancer	0.0286	0.117	CbGbCtD
Nortriptyline—CYP1A2—Sorafenib—liver cancer	0.0264	0.108	CbGbCtD
Nortriptyline—CYP2C9—Sorafenib—liver cancer	0.0238	0.0975	CbGbCtD
Nortriptyline—CYP2D6—Sorafenib—liver cancer	0.0217	0.0891	CbGbCtD
Nortriptyline—CYP3A4—Sorafenib—liver cancer	0.0138	0.0567	CbGbCtD
Nortriptyline—CYP2D6—Doxorubicin—liver cancer	0.0132	0.0541	CbGbCtD
Nortriptyline—CYP3A4—Doxorubicin—liver cancer	0.00839	0.0344	CbGbCtD
Nortriptyline—Oropharyngeal discomfort—Sorafenib—liver cancer	0.00189	0.0282	CcSEcCtD
Nortriptyline—Gynaecomastia—Sorafenib—liver cancer	0.00123	0.0184	CcSEcCtD
Nortriptyline—Hepatic function abnormal—Sorafenib—liver cancer	0.00114	0.017	CcSEcCtD
Nortriptyline—Bundle branch block—Epirubicin—liver cancer	0.00101	0.015	CcSEcCtD
Nortriptyline—Bundle branch block—Doxorubicin—liver cancer	0.000931	0.0139	CcSEcCtD
Nortriptyline—Erectile dysfunction—Sorafenib—liver cancer	0.000794	0.0119	CcSEcCtD
Nortriptyline—Weight decreased—Sorafenib—liver cancer	0.00078	0.0116	CcSEcCtD
Nortriptyline—Acute coronary syndrome—Sorafenib—liver cancer	0.000758	0.0113	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Sorafenib—liver cancer	0.000753	0.0112	CcSEcCtD
Nortriptyline—Myocardial infarction—Sorafenib—liver cancer	0.000753	0.0112	CcSEcCtD
Nortriptyline—Bone marrow depression—Epirubicin—liver cancer	0.000752	0.0112	CcSEcCtD
Nortriptyline—Jaundice—Sorafenib—liver cancer	0.000749	0.0112	CcSEcCtD
Nortriptyline—Stomatitis—Sorafenib—liver cancer	0.000749	0.0112	CcSEcCtD
Nortriptyline—Bone marrow depression—Doxorubicin—liver cancer	0.000696	0.0104	CcSEcCtD
Nortriptyline—Dermatitis atopic—Epirubicin—liver cancer	0.000686	0.0102	CcSEcCtD
Nortriptyline—Gingivitis—Epirubicin—liver cancer	0.000647	0.00966	CcSEcCtD
Nortriptyline—Tinnitus—Sorafenib—liver cancer	0.000643	0.0096	CcSEcCtD
Nortriptyline—Flushing—Sorafenib—liver cancer	0.00064	0.00956	CcSEcCtD
Nortriptyline—Dermatitis atopic—Doxorubicin—liver cancer	0.000635	0.00948	CcSEcCtD
Nortriptyline—Petechiae—Epirubicin—liver cancer	0.000617	0.00921	CcSEcCtD
Nortriptyline—Arrhythmia—Sorafenib—liver cancer	0.000616	0.0092	CcSEcCtD
Nortriptyline—Alopecia—Sorafenib—liver cancer	0.00061	0.0091	CcSEcCtD
Nortriptyline—Gingivitis—Doxorubicin—liver cancer	0.000598	0.00894	CcSEcCtD
Nortriptyline—Delirium—Epirubicin—liver cancer	0.00059	0.00881	CcSEcCtD
Nortriptyline—Dysgeusia—Sorafenib—liver cancer	0.000588	0.00878	CcSEcCtD
Nortriptyline—Petechiae—Doxorubicin—liver cancer	0.000571	0.00853	CcSEcCtD
Nortriptyline—Nocturia—Epirubicin—liver cancer	0.000547	0.00817	CcSEcCtD
Nortriptyline—Delirium—Doxorubicin—liver cancer	0.000546	0.00816	CcSEcCtD
Nortriptyline—Syncope—Sorafenib—liver cancer	0.000539	0.00804	CcSEcCtD
Nortriptyline—Leukopenia—Sorafenib—liver cancer	0.000538	0.00803	CcSEcCtD
Nortriptyline—Loss of consciousness—Sorafenib—liver cancer	0.000528	0.00788	CcSEcCtD
Nortriptyline—Atrioventricular block—Epirubicin—liver cancer	0.000523	0.00782	CcSEcCtD
Nortriptyline—Hypertension—Sorafenib—liver cancer	0.000518	0.00774	CcSEcCtD
Nortriptyline—Coordination abnormal—Epirubicin—liver cancer	0.000517	0.00772	CcSEcCtD
Nortriptyline—Ventricular tachycardia—Epirubicin—liver cancer	0.000508	0.00758	CcSEcCtD
Nortriptyline—Nocturia—Doxorubicin—liver cancer	0.000506	0.00756	CcSEcCtD
Nortriptyline—Dry mouth—Sorafenib—liver cancer	0.0005	0.00747	CcSEcCtD
Nortriptyline—Atrioventricular block—Doxorubicin—liver cancer	0.000484	0.00723	CcSEcCtD
Nortriptyline—Shock—Sorafenib—liver cancer	0.000482	0.0072	CcSEcCtD
Nortriptyline—Thrombocytopenia—Sorafenib—liver cancer	0.00048	0.00717	CcSEcCtD
Nortriptyline—Coordination abnormal—Doxorubicin—liver cancer	0.000478	0.00714	CcSEcCtD
Nortriptyline—Aplastic anaemia—Epirubicin—liver cancer	0.000477	0.00712	CcSEcCtD
Nortriptyline—Ventricular tachycardia—Doxorubicin—liver cancer	0.00047	0.00701	CcSEcCtD
Nortriptyline—Anorexia—Sorafenib—liver cancer	0.000467	0.00698	CcSEcCtD
Nortriptyline—Aplastic anaemia—Doxorubicin—liver cancer	0.000441	0.00659	CcSEcCtD
Nortriptyline—Dyspepsia—Sorafenib—liver cancer	0.000431	0.00644	CcSEcCtD
Nortriptyline—Decreased appetite—Sorafenib—liver cancer	0.000426	0.00636	CcSEcCtD
Nortriptyline—Fatigue—Sorafenib—liver cancer	0.000423	0.00631	CcSEcCtD
Nortriptyline—Hepatic function abnormal—Epirubicin—liver cancer	0.000422	0.0063	CcSEcCtD
Nortriptyline—Constipation—Sorafenib—liver cancer	0.000419	0.00626	CcSEcCtD
Nortriptyline—Vascular purpura—Epirubicin—liver cancer	0.000412	0.00615	CcSEcCtD
Nortriptyline—Eye pain—Epirubicin—liver cancer	0.000408	0.0061	CcSEcCtD
Nortriptyline—Hot flush—Epirubicin—liver cancer	0.000394	0.00588	CcSEcCtD
Nortriptyline—Menopausal symptoms—Epirubicin—liver cancer	0.000391	0.00583	CcSEcCtD
Nortriptyline—Hepatic function abnormal—Doxorubicin—liver cancer	0.00039	0.00583	CcSEcCtD
Nortriptyline—Urticaria—Sorafenib—liver cancer	0.000389	0.00581	CcSEcCtD
Nortriptyline—Abdominal pain—Sorafenib—liver cancer	0.000387	0.00579	CcSEcCtD
Nortriptyline—Body temperature increased—Sorafenib—liver cancer	0.000387	0.00579	CcSEcCtD
Nortriptyline—Purpura—Epirubicin—liver cancer	0.000382	0.00571	CcSEcCtD
Nortriptyline—Vascular purpura—Doxorubicin—liver cancer	0.000381	0.00569	CcSEcCtD
Nortriptyline—Eye pain—Doxorubicin—liver cancer	0.000378	0.00564	CcSEcCtD
Nortriptyline—Cerebrovascular accident—Epirubicin—liver cancer	0.000376	0.00562	CcSEcCtD
Nortriptyline—Hot flush—Doxorubicin—liver cancer	0.000365	0.00544	CcSEcCtD
Nortriptyline—Menopausal symptoms—Doxorubicin—liver cancer	0.000361	0.0054	CcSEcCtD
Nortriptyline—Hypersensitivity—Sorafenib—liver cancer	0.000361	0.00539	CcSEcCtD
Nortriptyline—Purpura—Doxorubicin—liver cancer	0.000354	0.00528	CcSEcCtD
Nortriptyline—Asthenia—Sorafenib—liver cancer	0.000352	0.00525	CcSEcCtD
Nortriptyline—Cerebrovascular accident—Doxorubicin—liver cancer	0.000348	0.0052	CcSEcCtD
Nortriptyline—Pruritus—Sorafenib—liver cancer	0.000347	0.00518	CcSEcCtD
Nortriptyline—Ataxia—Epirubicin—liver cancer	0.000347	0.00517	CcSEcCtD
Nortriptyline—Orthostatic hypotension—Epirubicin—liver cancer	0.000337	0.00503	CcSEcCtD
Nortriptyline—Diarrhoea—Sorafenib—liver cancer	0.000335	0.00501	CcSEcCtD
Nortriptyline—Dizziness—Sorafenib—liver cancer	0.000324	0.00484	CcSEcCtD
Nortriptyline—Ataxia—Doxorubicin—liver cancer	0.000321	0.00479	CcSEcCtD
Nortriptyline—Eosinophilia—Epirubicin—liver cancer	0.000315	0.00471	CcSEcCtD
Nortriptyline—Vomiting—Sorafenib—liver cancer	0.000312	0.00465	CcSEcCtD
Nortriptyline—Orthostatic hypotension—Doxorubicin—liver cancer	0.000311	0.00465	CcSEcCtD
Nortriptyline—Rash—Sorafenib—liver cancer	0.000309	0.00461	CcSEcCtD
Nortriptyline—Dermatitis—Sorafenib—liver cancer	0.000309	0.00461	CcSEcCtD
Nortriptyline—Headache—Sorafenib—liver cancer	0.000307	0.00458	CcSEcCtD
Nortriptyline—Pancytopenia—Epirubicin—liver cancer	0.000302	0.00452	CcSEcCtD
Nortriptyline—Clomipramine—GSTP1—liver cancer	0.000302	0.325	CrCbGaD
Nortriptyline—Pollakiuria—Epirubicin—liver cancer	0.000294	0.00439	CcSEcCtD
Nortriptyline—Eosinophilia—Doxorubicin—liver cancer	0.000292	0.00436	CcSEcCtD
Nortriptyline—Nausea—Sorafenib—liver cancer	0.000291	0.00435	CcSEcCtD
Nortriptyline—Weight increased—Epirubicin—liver cancer	0.00029	0.00433	CcSEcCtD
Nortriptyline—Weight decreased—Epirubicin—liver cancer	0.000288	0.0043	CcSEcCtD
Nortriptyline—Drowsiness—Epirubicin—liver cancer	0.000284	0.00424	CcSEcCtD
Nortriptyline—Pancytopenia—Doxorubicin—liver cancer	0.00028	0.00418	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Epirubicin—liver cancer	0.000278	0.00416	CcSEcCtD
Nortriptyline—Jaundice—Epirubicin—liver cancer	0.000277	0.00413	CcSEcCtD
Nortriptyline—Stomatitis—Epirubicin—liver cancer	0.000277	0.00413	CcSEcCtD
Nortriptyline—Sweating—Epirubicin—liver cancer	0.000272	0.00407	CcSEcCtD
Nortriptyline—Pollakiuria—Doxorubicin—liver cancer	0.000272	0.00407	CcSEcCtD
Nortriptyline—Weight increased—Doxorubicin—liver cancer	0.000268	0.004	CcSEcCtD
Nortriptyline—Weight decreased—Doxorubicin—liver cancer	0.000267	0.00398	CcSEcCtD
Nortriptyline—Agranulocytosis—Epirubicin—liver cancer	0.000265	0.00396	CcSEcCtD
Nortriptyline—Drowsiness—Doxorubicin—liver cancer	0.000263	0.00392	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Doxorubicin—liver cancer	0.000258	0.00385	CcSEcCtD
Nortriptyline—Stomatitis—Doxorubicin—liver cancer	0.000256	0.00382	CcSEcCtD
Nortriptyline—Jaundice—Doxorubicin—liver cancer	0.000256	0.00382	CcSEcCtD
Nortriptyline—Hepatitis—Epirubicin—liver cancer	0.000255	0.00381	CcSEcCtD
Nortriptyline—Hypoaesthesia—Epirubicin—liver cancer	0.000254	0.00379	CcSEcCtD
Nortriptyline—Sweating—Doxorubicin—liver cancer	0.000252	0.00376	CcSEcCtD
Nortriptyline—Oedema peripheral—Epirubicin—liver cancer	0.000251	0.00375	CcSEcCtD
Nortriptyline—Agranulocytosis—Doxorubicin—liver cancer	0.000245	0.00366	CcSEcCtD
Nortriptyline—Eye disorder—Epirubicin—liver cancer	0.000238	0.00356	CcSEcCtD
Nortriptyline—Tinnitus—Epirubicin—liver cancer	0.000238	0.00355	CcSEcCtD
Nortriptyline—Flushing—Epirubicin—liver cancer	0.000237	0.00353	CcSEcCtD
Nortriptyline—Hepatitis—Doxorubicin—liver cancer	0.000236	0.00352	CcSEcCtD
Nortriptyline—Hypoaesthesia—Doxorubicin—liver cancer	0.000235	0.0035	CcSEcCtD
Nortriptyline—Oedema peripheral—Doxorubicin—liver cancer	0.000232	0.00347	CcSEcCtD
Nortriptyline—Arrhythmia—Epirubicin—liver cancer	0.000228	0.0034	CcSEcCtD
Nortriptyline—Alopecia—Epirubicin—liver cancer	0.000225	0.00336	CcSEcCtD
Nortriptyline—Eye disorder—Doxorubicin—liver cancer	0.00022	0.00329	CcSEcCtD
Nortriptyline—Tinnitus—Doxorubicin—liver cancer	0.00022	0.00328	CcSEcCtD
Nortriptyline—Flushing—Doxorubicin—liver cancer	0.000219	0.00327	CcSEcCtD
Nortriptyline—Tension—Epirubicin—liver cancer	0.000218	0.00325	CcSEcCtD
Nortriptyline—Dysgeusia—Epirubicin—liver cancer	0.000217	0.00325	CcSEcCtD
Nortriptyline—Nervousness—Epirubicin—liver cancer	0.000216	0.00322	CcSEcCtD
Nortriptyline—Arrhythmia—Doxorubicin—liver cancer	0.000211	0.00315	CcSEcCtD
Nortriptyline—Vision blurred—Epirubicin—liver cancer	0.000209	0.00312	CcSEcCtD
Nortriptyline—Alopecia—Doxorubicin—liver cancer	0.000208	0.00311	CcSEcCtD
Nortriptyline—Ill-defined disorder—Epirubicin—liver cancer	0.000206	0.00307	CcSEcCtD
Nortriptyline—Agitation—Epirubicin—liver cancer	0.000204	0.00305	CcSEcCtD
Nortriptyline—Tension—Doxorubicin—liver cancer	0.000202	0.00301	CcSEcCtD
Nortriptyline—Dysgeusia—Doxorubicin—liver cancer	0.000201	0.003	CcSEcCtD
Nortriptyline—Malaise—Epirubicin—liver cancer	0.0002	0.00299	CcSEcCtD
Nortriptyline—Nervousness—Doxorubicin—liver cancer	0.000199	0.00298	CcSEcCtD
Nortriptyline—Syncope—Epirubicin—liver cancer	0.000199	0.00297	CcSEcCtD
Nortriptyline—Leukopenia—Epirubicin—liver cancer	0.000199	0.00297	CcSEcCtD
Nortriptyline—Palpitations—Epirubicin—liver cancer	0.000196	0.00293	CcSEcCtD
Nortriptyline—Loss of consciousness—Epirubicin—liver cancer	0.000195	0.00291	CcSEcCtD
Nortriptyline—Vision blurred—Doxorubicin—liver cancer	0.000194	0.00289	CcSEcCtD
Nortriptyline—Convulsion—Epirubicin—liver cancer	0.000192	0.00287	CcSEcCtD
Nortriptyline—Hypertension—Epirubicin—liver cancer	0.000192	0.00286	CcSEcCtD
Nortriptyline—Ill-defined disorder—Doxorubicin—liver cancer	0.000191	0.00285	CcSEcCtD
Nortriptyline—Agitation—Doxorubicin—liver cancer	0.000189	0.00282	CcSEcCtD
Nortriptyline—Anxiety—Epirubicin—liver cancer	0.000188	0.00281	CcSEcCtD
Nortriptyline—Discomfort—Epirubicin—liver cancer	0.000187	0.00279	CcSEcCtD
Nortriptyline—Malaise—Doxorubicin—liver cancer	0.000185	0.00277	CcSEcCtD
Nortriptyline—Dry mouth—Epirubicin—liver cancer	0.000185	0.00276	CcSEcCtD
Nortriptyline—Syncope—Doxorubicin—liver cancer	0.000184	0.00275	CcSEcCtD
Nortriptyline—Leukopenia—Doxorubicin—liver cancer	0.000184	0.00274	CcSEcCtD
Nortriptyline—Confusional state—Epirubicin—liver cancer	0.000183	0.00273	CcSEcCtD
Nortriptyline—Palpitations—Doxorubicin—liver cancer	0.000181	0.00271	CcSEcCtD
Nortriptyline—Oedema—Epirubicin—liver cancer	0.000181	0.0027	CcSEcCtD
Nortriptyline—Loss of consciousness—Doxorubicin—liver cancer	0.00018	0.0027	CcSEcCtD
Nortriptyline—Shock—Epirubicin—liver cancer	0.000178	0.00266	CcSEcCtD
Nortriptyline—Convulsion—Doxorubicin—liver cancer	0.000178	0.00266	CcSEcCtD
Nortriptyline—Thrombocytopenia—Epirubicin—liver cancer	0.000177	0.00265	CcSEcCtD
Nortriptyline—Hypertension—Doxorubicin—liver cancer	0.000177	0.00265	CcSEcCtD
Nortriptyline—Tachycardia—Epirubicin—liver cancer	0.000177	0.00264	CcSEcCtD
Nortriptyline—Hyperhidrosis—Epirubicin—liver cancer	0.000175	0.00261	CcSEcCtD
Nortriptyline—Anxiety—Doxorubicin—liver cancer	0.000174	0.0026	CcSEcCtD
Nortriptyline—Discomfort—Doxorubicin—liver cancer	0.000173	0.00258	CcSEcCtD
Nortriptyline—Anorexia—Epirubicin—liver cancer	0.000173	0.00258	CcSEcCtD
Nortriptyline—Dry mouth—Doxorubicin—liver cancer	0.000171	0.00255	CcSEcCtD
Nortriptyline—Hypotension—Epirubicin—liver cancer	0.000169	0.00253	CcSEcCtD
Nortriptyline—Confusional state—Doxorubicin—liver cancer	0.000169	0.00252	CcSEcCtD
Nortriptyline—Oedema—Doxorubicin—liver cancer	0.000168	0.0025	CcSEcCtD
Nortriptyline—Shock—Doxorubicin—liver cancer	0.000165	0.00246	CcSEcCtD
Nortriptyline—Thrombocytopenia—Doxorubicin—liver cancer	0.000164	0.00245	CcSEcCtD
Nortriptyline—Insomnia—Epirubicin—liver cancer	0.000164	0.00245	CcSEcCtD
Nortriptyline—Tachycardia—Doxorubicin—liver cancer	0.000164	0.00244	CcSEcCtD
Nortriptyline—Paraesthesia—Epirubicin—liver cancer	0.000163	0.00243	CcSEcCtD
Nortriptyline—Hyperhidrosis—Doxorubicin—liver cancer	0.000162	0.00242	CcSEcCtD
Nortriptyline—Somnolence—Epirubicin—liver cancer	0.000161	0.0024	CcSEcCtD
Nortriptyline—Anorexia—Doxorubicin—liver cancer	0.00016	0.00239	CcSEcCtD
Nortriptyline—Dyspepsia—Epirubicin—liver cancer	0.000159	0.00238	CcSEcCtD
Nortriptyline—Decreased appetite—Epirubicin—liver cancer	0.000157	0.00235	CcSEcCtD
Nortriptyline—Hypotension—Doxorubicin—liver cancer	0.000157	0.00234	CcSEcCtD
Nortriptyline—Fatigue—Epirubicin—liver cancer	0.000156	0.00233	CcSEcCtD
Nortriptyline—Constipation—Epirubicin—liver cancer	0.000155	0.00231	CcSEcCtD
Nortriptyline—Insomnia—Doxorubicin—liver cancer	0.000152	0.00226	CcSEcCtD
Nortriptyline—Paraesthesia—Doxorubicin—liver cancer	0.00015	0.00225	CcSEcCtD
Nortriptyline—Feeling abnormal—Epirubicin—liver cancer	0.000149	0.00223	CcSEcCtD
Nortriptyline—Somnolence—Doxorubicin—liver cancer	0.000149	0.00222	CcSEcCtD
Nortriptyline—Oxcarbazepine—ALB—liver cancer	0.000148	0.16	CrCbGaD
Nortriptyline—Dyspepsia—Doxorubicin—liver cancer	0.000148	0.0022	CcSEcCtD
Nortriptyline—Decreased appetite—Doxorubicin—liver cancer	0.000146	0.00218	CcSEcCtD
Nortriptyline—Fatigue—Doxorubicin—liver cancer	0.000144	0.00216	CcSEcCtD
Nortriptyline—Urticaria—Epirubicin—liver cancer	0.000144	0.00215	CcSEcCtD
Nortriptyline—Constipation—Doxorubicin—liver cancer	0.000143	0.00214	CcSEcCtD
Nortriptyline—Abdominal pain—Epirubicin—liver cancer	0.000143	0.00214	CcSEcCtD
Nortriptyline—Body temperature increased—Epirubicin—liver cancer	0.000143	0.00214	CcSEcCtD
Nortriptyline—Feeling abnormal—Doxorubicin—liver cancer	0.000138	0.00206	CcSEcCtD
Nortriptyline—Hypersensitivity—Epirubicin—liver cancer	0.000133	0.00199	CcSEcCtD
Nortriptyline—Urticaria—Doxorubicin—liver cancer	0.000133	0.00199	CcSEcCtD
Nortriptyline—Abdominal pain—Doxorubicin—liver cancer	0.000132	0.00198	CcSEcCtD
Nortriptyline—Body temperature increased—Doxorubicin—liver cancer	0.000132	0.00198	CcSEcCtD
Nortriptyline—Asthenia—Epirubicin—liver cancer	0.00013	0.00194	CcSEcCtD
Nortriptyline—Pruritus—Epirubicin—liver cancer	0.000128	0.00191	CcSEcCtD
Nortriptyline—Desipramine—CYP2E1—liver cancer	0.000125	0.134	CrCbGaD
Nortriptyline—Diarrhoea—Epirubicin—liver cancer	0.000124	0.00185	CcSEcCtD
Nortriptyline—Hypersensitivity—Doxorubicin—liver cancer	0.000123	0.00184	CcSEcCtD
Nortriptyline—Asthenia—Doxorubicin—liver cancer	0.00012	0.0018	CcSEcCtD
Nortriptyline—Dizziness—Epirubicin—liver cancer	0.00012	0.00179	CcSEcCtD
Nortriptyline—Pruritus—Doxorubicin—liver cancer	0.000119	0.00177	CcSEcCtD
Nortriptyline—Vomiting—Epirubicin—liver cancer	0.000115	0.00172	CcSEcCtD
Nortriptyline—Diarrhoea—Doxorubicin—liver cancer	0.000115	0.00171	CcSEcCtD
Nortriptyline—Rash—Epirubicin—liver cancer	0.000114	0.00171	CcSEcCtD
Nortriptyline—Dermatitis—Epirubicin—liver cancer	0.000114	0.0017	CcSEcCtD
Nortriptyline—Headache—Epirubicin—liver cancer	0.000113	0.00169	CcSEcCtD
Nortriptyline—Dizziness—Doxorubicin—liver cancer	0.000111	0.00165	CcSEcCtD
Nortriptyline—Nausea—Epirubicin—liver cancer	0.000108	0.00161	CcSEcCtD
Nortriptyline—Vomiting—Doxorubicin—liver cancer	0.000107	0.00159	CcSEcCtD
Nortriptyline—Imipramine—CYP2E1—liver cancer	0.000106	0.114	CrCbGaD
Nortriptyline—Rash—Doxorubicin—liver cancer	0.000106	0.00158	CcSEcCtD
Nortriptyline—Dermatitis—Doxorubicin—liver cancer	0.000106	0.00158	CcSEcCtD
Nortriptyline—Amitriptyline—CYP2E1—liver cancer	0.000105	0.113	CrCbGaD
Nortriptyline—Headache—Doxorubicin—liver cancer	0.000105	0.00157	CcSEcCtD
Nortriptyline—Nausea—Doxorubicin—liver cancer	9.95e-05	0.00149	CcSEcCtD
Nortriptyline—Clomipramine—ALB—liver cancer	8.52e-05	0.0917	CrCbGaD
Nortriptyline—Amitriptyline—ALB—liver cancer	5.78e-05	0.0622	CrCbGaD
Nortriptyline—CHRM3—Signaling Pathways—CDKN1B—liver cancer	4.92e-06	4.07e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—AKT1—liver cancer	4.91e-06	4.06e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—IL6—liver cancer	4.91e-06	4.06e-05	CbGpPWpGaD
Nortriptyline—HTR2A—GPCR downstream signaling—AKT1—liver cancer	4.91e-06	4.06e-05	CbGpPWpGaD
Nortriptyline—HRH1—GPCR downstream signaling—AKT1—liver cancer	4.9e-06	4.05e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CG—liver cancer	4.89e-06	4.04e-05	CbGpPWpGaD
Nortriptyline—CHRM1—GPCR downstream signaling—AKT1—liver cancer	4.88e-06	4.04e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—TP53—liver cancer	4.87e-06	4.03e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CDKN1B—liver cancer	4.87e-06	4.03e-05	CbGpPWpGaD
Nortriptyline—CHRM3—GPCR downstream signaling—AKT1—liver cancer	4.86e-06	4.02e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CASP3—liver cancer	4.86e-06	4.02e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	4.86e-06	4.02e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—IL2—liver cancer	4.85e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CASP3—liver cancer	4.85e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CG—liver cancer	4.85e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—IL2—liver cancer	4.84e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PPARA—liver cancer	4.84e-06	4e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CASP3—liver cancer	4.83e-06	4e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—IL6—liver cancer	4.83e-06	3.99e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—IL2—liver cancer	4.83e-06	3.99e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CASP3—liver cancer	4.82e-06	3.99e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—IL6—liver cancer	4.82e-06	3.99e-05	CbGpPWpGaD
Nortriptyline—CHRM2—GPCR downstream signaling—AKT1—liver cancer	4.82e-06	3.98e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—IL2—liver cancer	4.81e-06	3.98e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CCND1—liver cancer	4.81e-06	3.98e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	4.8e-06	3.97e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—IL6—liver cancer	4.8e-06	3.97e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—JUN—liver cancer	4.8e-06	3.97e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—IL6—liver cancer	4.79e-06	3.96e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—VEGFA—liver cancer	4.77e-06	3.95e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CASP3—liver cancer	4.77e-06	3.95e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—IL2—liver cancer	4.77e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CTNNB1—liver cancer	4.76e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CASP3—liver cancer	4.76e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—IL2—liver cancer	4.75e-06	3.93e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—PIK3CA—liver cancer	4.75e-06	3.93e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—VEGFA—liver cancer	4.75e-06	3.93e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—IL6—liver cancer	4.74e-06	3.92e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CCND1—liver cancer	4.73e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—IL6—liver cancer	4.73e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—STAT3—liver cancer	4.73e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—JUN—liver cancer	4.72e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CCND1—liver cancer	4.72e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PPARG—liver cancer	4.72e-06	3.9e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—JUN—liver cancer	4.71e-06	3.9e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CCND1—liver cancer	4.71e-06	3.89e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—STAT3—liver cancer	4.7e-06	3.89e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—JUN—liver cancer	4.7e-06	3.88e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CCND1—liver cancer	4.69e-06	3.88e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CTNNB1—liver cancer	4.69e-06	3.88e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—GSTP1—liver cancer	4.68e-06	3.88e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—JUN—liver cancer	4.68e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PPARG—liver cancer	4.68e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CTNNB1—liver cancer	4.67e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CD—liver cancer	4.67e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MMP9—liver cancer	4.67e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—HRAS—liver cancer	4.66e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CTNNB1—liver cancer	4.66e-06	3.85e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—KRAS—liver cancer	4.66e-06	3.85e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CDKN1A—liver cancer	4.65e-06	3.85e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CCND1—liver cancer	4.65e-06	3.84e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CTNNB1—liver cancer	4.65e-06	3.84e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—JUN—liver cancer	4.64e-06	3.83e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CCND1—liver cancer	4.63e-06	3.83e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—JUN—liver cancer	4.62e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—HMOX1—liver cancer	4.62e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—ALB—liver cancer	4.61e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CTNNB1—liver cancer	4.6e-06	3.81e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—TP53—liver cancer	4.6e-06	3.8e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MMP9—liver cancer	4.59e-06	3.8e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	4.59e-06	3.79e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MMP9—liver cancer	4.58e-06	3.79e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CDKN1A—liver cancer	4.58e-06	3.79e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MMP9—liver cancer	4.57e-06	3.78e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CDKN1A—liver cancer	4.57e-06	3.78e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MMP9—liver cancer	4.55e-06	3.77e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CDKN1A—liver cancer	4.55e-06	3.77e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—PIK3CA—liver cancer	4.55e-06	3.76e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—VEGFA—liver cancer	4.55e-06	3.76e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MAPK8—liver cancer	4.54e-06	3.76e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CDKN1A—liver cancer	4.54e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CB—liver cancer	4.54e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—AKT1—liver cancer	4.53e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MMP9—liver cancer	4.51e-06	3.73e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—STAT3—liver cancer	4.5e-06	3.72e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MMP9—liver cancer	4.5e-06	3.72e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CDKN1A—liver cancer	4.49e-06	3.72e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	4.48e-06	3.71e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MAPK8—liver cancer	4.47e-06	3.7e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—IL6—liver cancer	4.46e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MAPK8—liver cancer	4.46e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—AKT1—liver cancer	4.45e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—AKT1—liver cancer	4.45e-06	3.68e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MAPK8—liver cancer	4.44e-06	3.68e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—AKT1—liver cancer	4.43e-06	3.67e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MAPK8—liver cancer	4.43e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—AKT1—liver cancer	4.42e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—TP53—liver cancer	4.4e-06	3.64e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—HRAS—liver cancer	4.4e-06	3.64e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—MYC—liver cancer	4.39e-06	3.63e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MAPK8—liver cancer	4.39e-06	3.63e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TGFB1—liver cancer	4.38e-06	3.62e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—AKT1—liver cancer	4.37e-06	3.62e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MAPK8—liver cancer	4.37e-06	3.62e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—MYC—liver cancer	4.37e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—AKT1—liver cancer	4.36e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TGFB1—liver cancer	4.36e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.34e-06	3.59e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—PIK3CA—liver cancer	4.31e-06	3.56e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—GSTM1—liver cancer	4.31e-06	3.56e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CD—liver cancer	4.3e-06	3.56e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	4.28e-06	3.54e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CD—liver cancer	4.26e-06	3.52e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—ALB—liver cancer	4.24e-06	3.51e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—HRAS—liver cancer	4.21e-06	3.48e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—IL6—liver cancer	4.21e-06	3.48e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—ALB—liver cancer	4.21e-06	3.48e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—VEGFA—liver cancer	4.19e-06	3.47e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—MYC—liver cancer	4.18e-06	3.46e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TGFB1—liver cancer	4.17e-06	3.45e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—STAT3—liver cancer	4.15e-06	3.43e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CG—liver cancer	4.14e-06	3.43e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—TP53—liver cancer	4.14e-06	3.42e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—VEGFA—liver cancer	4.12e-06	3.41e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—VEGFA—liver cancer	4.12e-06	3.4e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—AKT1—liver cancer	4.12e-06	3.4e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—VEGFA—liver cancer	4.1e-06	3.39e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—VEGFA—liver cancer	4.09e-06	3.38e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—STAT3—liver cancer	4.08e-06	3.38e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CYP1A1—liver cancer	4.08e-06	3.38e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—STAT3—liver cancer	4.08e-06	3.37e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CB—liver cancer	4.07e-06	3.37e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—STAT3—liver cancer	4.06e-06	3.36e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—KRAS—liver cancer	4.06e-06	3.36e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—VEGFA—liver cancer	4.05e-06	3.35e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—STAT3—liver cancer	4.05e-06	3.35e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—VEGFA—liver cancer	4.04e-06	3.34e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—KRAS—liver cancer	4.04e-06	3.34e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—IL6—liver cancer	4.03e-06	3.33e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—STAT3—liver cancer	4.01e-06	3.32e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—STAT3—liver cancer	4e-06	3.31e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PPARG—liver cancer	4e-06	3.31e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—HRAS—liver cancer	3.96e-06	3.27e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—AKT1—liver cancer	3.88e-06	3.21e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—KRAS—liver cancer	3.87e-06	3.2e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MYC—liver cancer	3.86e-06	3.19e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TGFB1—liver cancer	3.85e-06	3.18e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—PIK3CA—liver cancer	3.82e-06	3.16e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—MTHFR—liver cancer	3.8e-06	3.15e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MYC—liver cancer	3.79e-06	3.14e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—IL6—liver cancer	3.79e-06	3.13e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MYC—liver cancer	3.79e-06	3.13e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TGFB1—liver cancer	3.79e-06	3.13e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TGFB1—liver cancer	3.78e-06	3.12e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MYC—liver cancer	3.77e-06	3.12e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TGFB1—liver cancer	3.77e-06	3.11e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MYC—liver cancer	3.76e-06	3.11e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TGFB1—liver cancer	3.75e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CB—liver cancer	3.75e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PPARA—liver cancer	3.73e-06	3.09e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—PIK3CA—liver cancer	3.73e-06	3.08e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MYC—liver cancer	3.73e-06	3.08e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—AKT1—liver cancer	3.72e-06	3.08e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TGFB1—liver cancer	3.72e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MYC—liver cancer	3.72e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CB—liver cancer	3.71e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—PIK3CA—liver cancer	3.71e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TGFB1—liver cancer	3.71e-06	3.07e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CD—liver cancer	3.64e-06	3.01e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TP53—liver cancer	3.61e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—ALB—liver cancer	3.59e-06	2.97e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TP53—liver cancer	3.59e-06	2.97e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—KRAS—liver cancer	3.56e-06	2.95e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	3.55e-06	2.94e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—AKT1—liver cancer	3.52e-06	2.91e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—KRAS—liver cancer	3.51e-06	2.9e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—KRAS—liver cancer	3.5e-06	2.89e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—AKT1—liver cancer	3.5e-06	2.89e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—KRAS—liver cancer	3.49e-06	2.88e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—KRAS—liver cancer	3.48e-06	2.88e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—HRAS—liver cancer	3.45e-06	2.85e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—KRAS—liver cancer	3.44e-06	2.85e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TP53—liver cancer	3.44e-06	2.84e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—KRAS—liver cancer	3.43e-06	2.84e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—HRAS—liver cancer	3.43e-06	2.84e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—IL6—liver cancer	3.3e-06	2.73e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—HRAS—liver cancer	3.29e-06	2.72e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—IL6—liver cancer	3.28e-06	2.72e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PIK3CA—liver cancer	3.27e-06	2.71e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PIK3CA—liver cancer	3.22e-06	2.66e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PIK3CA—liver cancer	3.22e-06	2.66e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PIK3CA—liver cancer	3.21e-06	2.66e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PIK3CA—liver cancer	3.21e-06	2.66e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PIK3CA—liver cancer	3.2e-06	2.65e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CG—liver cancer	3.2e-06	2.64e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PIK3CA—liver cancer	3.19e-06	2.64e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CB—liver cancer	3.17e-06	2.63e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TP53—liver cancer	3.17e-06	2.62e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PIK3CA—liver cancer	3.16e-06	2.62e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	3.15e-06	2.61e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—IL6—liver cancer	3.14e-06	2.6e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—AKT1—liver cancer	3.12e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TP53—liver cancer	3.12e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TP53—liver cancer	3.11e-06	2.57e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TP53—liver cancer	3.1e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TP53—liver cancer	3.09e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PPARG—liver cancer	3.09e-06	2.55e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TP53—liver cancer	3.06e-06	2.53e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TP53—liver cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—AKT1—liver cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—AKT1—liver cancer	3.03e-06	2.51e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—HRAS—liver cancer	3.03e-06	2.51e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—HRAS—liver cancer	2.98e-06	2.47e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—HRAS—liver cancer	2.97e-06	2.46e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—HRAS—liver cancer	2.96e-06	2.45e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—HRAS—liver cancer	2.95e-06	2.44e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—HRAS—liver cancer	2.93e-06	2.42e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—HRAS—liver cancer	2.92e-06	2.41e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—AKT1—liver cancer	2.9e-06	2.4e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—IL6—liver cancer	2.9e-06	2.4e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—IL6—liver cancer	2.85e-06	2.36e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—IL6—liver cancer	2.85e-06	2.35e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—IL6—liver cancer	2.84e-06	2.35e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—IL6—liver cancer	2.83e-06	2.34e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CD—liver cancer	2.81e-06	2.32e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—IL6—liver cancer	2.8e-06	2.32e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—IL6—liver cancer	2.79e-06	2.31e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ALB—liver cancer	2.77e-06	2.29e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CA—liver cancer	2.77e-06	2.29e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—AKT1—liver cancer	2.67e-06	2.21e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—AKT1—liver cancer	2.63e-06	2.18e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—AKT1—liver cancer	2.63e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—AKT1—liver cancer	2.63e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—AKT1—liver cancer	2.62e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—AKT1—liver cancer	2.62e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—AKT1—liver cancer	2.61e-06	2.16e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—AKT1—liver cancer	2.58e-06	2.14e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—AKT1—liver cancer	2.58e-06	2.13e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CA—liver cancer	2.48e-06	2.05e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CB—liver cancer	2.45e-06	2.03e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CA—liver cancer	2.28e-06	1.89e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CA—liver cancer	2.26e-06	1.87e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—AKT1—liver cancer	2.26e-06	1.87e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—AKT1—liver cancer	2.03e-06	1.68e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CA—liver cancer	1.93e-06	1.6e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—AKT1—liver cancer	1.87e-06	1.54e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—AKT1—liver cancer	1.85e-06	1.53e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—AKT1—liver cancer	1.58e-06	1.31e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CA—liver cancer	1.49e-06	1.24e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—AKT1—liver cancer	1.22e-06	1.01e-05	CbGpPWpGaD
